drugset / Trial / NCT05733715
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Phase 0
Recruiting
30 enrolled
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
Timeline
- Start
- 2023-05-03
- Primary completion
- 2026-06
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 4 mg | Oral |
| Subject | Lenvatinib | Small molecule | 10 mg | Oral |
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |